The Biotech Growth Trust Plc - Transaction in Own Shares

·1-min read

For immediate release

26 May 2023


(the "Company")


Notification is given, pursuant to the authority granted at Annual General Meeting of the Company held on 19 July 2022 to make market purchases of the Company's own shares up to an aggregate maximum of 6,134,167 that a market total of 100,000 Ordinary shares of 25p each in the capital of the Company were purchased today for cancellation by the Company at a price of 840.76 pence per share.

Following this transaction and in conformity with the provisions of the Transparency Directive, the Company hereby notifies the market that the total number of Ordinary shares that the Company has in issue, less the total number of Ordinary shares bought back for cancellation by the Company following such purchase, and therefore, the total number of voting rights in the Company is 37,900,027. The Company does not currently hold any Ordinary shares in treasury.

The figure of 37,900,027 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For and on behalf of

Frostrow Capital LLP

Company Secretary

For further information, please contact:

Mark Pope

Frostrow Capital LLP

Tel: 020 3 170 4913